Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease
Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa).
A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It’s Time for Companies to Act Like the Climate Crisis is a Health Crisis
Right now, delegations are descending upon Glasgow for the 26th annual United Nations Climate Change Conference (COP26) – with more than 100 world leaders gathering to accelerate climate action to meet goals set by the Paris Agreement and the UN Framework Convention on Climate Change.
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
September 23, 2021 – In 2020, Biogen launched its signature Healthy Climate, Healthy Lives™ initiative, a groundbreaking $250 million, 20-year commitment to address the deeply interrelated issues of climate, health, and equity. Biogen is the first Fortune 500 company to commit to becoming fossil
Biogen and Eisai Update for the Alzheimer’s Disease Community
CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 23, 2021 – Biogen (Nasdaq: BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co., Ltd. today issued the following statement: On June 7, 2021, ADUHELM™ (aducanumab-avwa) 100 mg/mL solution for injection was granted accelerated approval by the U.S. Food and Drug Administration (FDA). We are committed to responding to questions from the Alzheimer’s disease community and providing more details about our plans.
A Letter from Biogen’s CEO on ADUHELM
Today, on behalf of my Biogen colleagues, I am incredibly humbled to share that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELMTM (aducanumab-avwa), the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque. We come
Biogen Statement about Director and Chair of the Compensation and Management Development Committee Robert W. Pangia
Robert W. Pangia, who has served as a Biogen director since 1997, will retire from the company’s Board this year, effective at the annual meeting of stockholders. Biogen and the Board of Directors would like to thank Bob for his decades-long service and invaluable support.
A statement about Biogen Political Action Committee
Following last week’s deeply concerning events in Washington DC, we are suspending all political donations to allow a thorough review of our political contribution criteria and policies. Biogen supports the rule of law and democratic process and calls for a peaceful transition of power.
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
CAMBRIDGE, Mass. and TOKYO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted 1 yes, 8 no and 2 uncertain on the question, “Does Study 302 (EMERGE), viewed independently and without regard for
Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab
In 2020, the cost of Alzheimer’s in the U.S. is estimated to be over $500 billion, impacting countless patient, family and caregiver lives. If approved, aducanumab may slow clinical decline and potentially help patients maintain independence longer. This could constitute an important breakthrough,
Statement about the FDA advisory committee on aducanumab
On September 29, 2020, it was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual advisory committee meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to review data supporting the Biologics License Application (BLA)